By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for QGC001
Email this page to a colleague
What is the drug development status for QGC001?
QGC001 is an investigational drug.
There have been 10 clinical trials for QGC001.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2020.
The most common disease conditions in clinical trials are Hypertension, Ventricular Dysfunction, and Myocardial Infarction. The leading clinical trial sponsors are Quantum Genomics SA, PRA Health Sciences, and Eurofins Optimed.
There are three US patents protecting this investigational drug and forty-seven international patents.
Summary for QGC001
| US Patents | 3 |
| International Patents | 47 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2020-03-01) |
| Vendors | 9 |
Recent Clinical Trials for QGC001
| Title | Sponsor | Phase |
|---|---|---|
| Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension | PRA Health Sciences | Phase 3 |
| Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension | Quantum Genomics SA | Phase 3 |
| Firibastat in Treatment-resistant Hypertension | Quantum Genomics SA | Phase 3 |
Clinical Trial Summary for QGC001
Top disease conditions for QGC001
Top clinical trial sponsors for QGC001
US Patents for QGC001
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| QGC001 | Get Started Free | Derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same | Institute National de la Sante et de la Recherche Medicale (Inserm) (Paris Cedex, FR) | Get Started Free |
| QGC001 | Get Started Free | Method for the preparation of (3S, 3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) | QUANTUM GENOMICS (Paris, FR) | Get Started Free |
| QGC001 | Get Started Free | Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) | QUANTUM GENOMICS (Massy, FR) | Get Started Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for QGC001
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| QGC001 | Austria | AT455097 | 2023-08-06 | Get Started Free |
| QGC001 | Canada | CA2533432 | 2023-08-06 | Get Started Free |
| QGC001 | Cyprus | CY1109950 | 2023-08-06 | Get Started Free |
| QGC001 | Germany | DE602004025119 | 2023-08-06 | Get Started Free |
| QGC001 | Denmark | DK1651596 | 2023-08-06 | Get Started Free |
| QGC001 | European Patent Office | EP1651596 | 2023-08-06 | Get Started Free |
| QGC001 | Spain | ES2339354 | 2023-08-06 | Get Started Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
